Literature DB >> 17611586

Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.

B Liehl1, J Hlavaty, R Moldzio, Z Tonar, H Unger, B Salmons, W H Günzburg, M Renner.   

Abstract

Lentiviral vectors have proven to be promising tools for transduction of brain cells in vivo and in vitro. In this study, we have examined the central nervous system (CNS) transduction efficiencies and patterns of a self-inactivating simian immunodeficiency virus (SIVmac)-derived lentiviral vector pseudotyped with glycoproteins from the vesicular stomatitis virus (VSV-G), the amphotropic murine leukemia virus (MLV4070Aenv), the lymphocytic choriomeningitis virus (LCMV-GP), the Ross River virus (RRV-GP) and the rabies virus (RV-G). All glycoproteins were efficiently incorporated into SIV virions, allowing efficient transduction of neuronal cell lines as well as of primary dissociated mouse brain cell cultures. After injection of highly concentrated vector stocks into the striatum of adult mice, quantitative analyses revealed high transduction efficiency with VSV-G pseudotypes, while LCMV-GP and RV-G pseudotypes exhibited moderate transduction efficiencies. MLV4070Aenv and RRV-GP pseudotypes, however, showed only weak levels of transduction after stereotactic injection into the brain. Regarding cell tropism in vivo, VSV-G-pseudotyped SIV vectors transduced neuronal as well as glial cells, whereas all other pseudotypes preferentially transduced neuroglial cells. In addition, we analyzed the influence of the central polypurine tract (cPPT) in context of the VSV-G-pseudotyped SIV transfer vector for infection of brain cells. Deletion of the cPPT sequence from the transfer vector decreased the in vivo transduction efficiency by fourfold, and, more importantly, this modification changed the transduction pattern, since these vectors were no longer able to infect neuronal cells in vivo. Vector injection into the brain did elicit a humoral immune response in the injected hemisphere; however, no gross signs of inflammation could be detected. Analysis of the biodistribution of the vector revealed that, besides the injected brain region, no vector-specific sequences could be detected in any of the organs evaluated. These data indicate SIV vectors as efficient gene delivery vehicles for the treatment of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611586     DOI: 10.1038/sj.gt.3302988

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.

Authors:  Elena Grabski; Zoe Waibler; Silke Schüle; Björn-Philipp Kloke; Linda Y Sender; Sylvia Panitz; Klaus Cichutek; Matthias Schweizer; Ulrich Kalinke
Journal:  Mol Biotechnol       Date:  2011-03       Impact factor: 2.695

2.  Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Authors:  Juraj Hlavaty; Gerrit Jandl; Melissa Liszt; Helga Petznek; Marielle König-Schuster; Jenny Sedlak; Monika Egerbacher; Jakob Weissenberger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Neurooncol       Date:  2010-07-11       Impact factor: 4.130

3.  Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.

Authors:  Brigitte Anliker; Tobias Abel; Sabrina Kneissl; Juraj Hlavaty; Antonio Caputi; Julia Brynza; Irene C Schneider; Robert C Münch; Helga Petznek; Roland E Kontermann; Ulrike Koehl; Ian C D Johnston; Kari Keinänen; Ulrike C Müller; Christine Hohenadl; Hannah Monyer; Klaus Cichutek; Christian J Buchholz
Journal:  Nat Methods       Date:  2010-10-10       Impact factor: 28.547

4.  Tropism, intracerebral distribution, and transduction efficiency of HIV- and SIV-based lentiviral vectors after injection into the mouse brain: a qualitative and quantitative in vivo study.

Authors:  Juraj Hlavatý; Zbyněk Tonar; Matthias Renner; Sylvia Panitz; Helga Petznek; Matthias Schweizer; Silke Schüle; Björn-Philipp Kloke; Rudolf Moldzio; Kirsti Witter
Journal:  Histochem Cell Biol       Date:  2017-04-10       Impact factor: 4.304

5.  Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain.

Authors:  Luis Quintino; Angrit Namislo; Marcus Davidsson; Ludivine S Breger; Patrick Kavanagh; Martino Avallone; Erika Elgstrand-Wettergren; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther Methods Clin Dev       Date:  2018-09-04       Impact factor: 6.698

6.  GluA4-Targeted AAV Vectors Deliver Genes Selectively to Interneurons while Relying on the AAV Receptor for Entry.

Authors:  Jessica Hartmann; Frederic B Thalheimer; Felix Höpfner; Thomas Kerzel; Konstantin Khodosevich; Diego García-González; Hannah Monyer; Ilka Diester; Hildegard Büning; Jan E Carette; Pascal Fries; Christian J Buchholz
Journal:  Mol Ther Methods Clin Dev       Date:  2019-07-23       Impact factor: 6.698

7.  Tackling obstacles for gene therapy targeting neurons: disrupting perineural nets with hyaluronidase improves transduction.

Authors:  Klaus Wanisch; Stjepana Kovac; Stephanie Schorge
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

8.  Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer.

Authors:  Thais Federici; Robert Kutner; Xian-Yang Zhang; Hitoshi Kuroda; Noël Tordo; Nicholas M Boulis; Jakob Reiser
Journal:  Genet Vaccines Ther       Date:  2009-01-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.